Cargando…

Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics

OBJECTIVES: Till date, mutations in the genes PAX3 and MITF have been described in Waardenburg syndrome (WS), which is clinically characterised by congenital hearing loss and pigmentation anomalies. Our study intended to determine the frequency of mutations and deletions in these genes, to assess th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wildhardt, Gabriele, Zirn, Birgit, Graul-Neumann, Luitgard M, Wechtenbruch, Juliane, Suckfüll, Markus, Buske, Annegret, Bohring, Axel, Kubisch, Christian, Vogt, Stefanie, Strobl-Wildemann, Gertrud, Greally, Marie, Bartsch, Oliver, Steinberger, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612789/
https://www.ncbi.nlm.nih.gov/pubmed/23512835
http://dx.doi.org/10.1136/bmjopen-2012-001917
_version_ 1782264686236925952
author Wildhardt, Gabriele
Zirn, Birgit
Graul-Neumann, Luitgard M
Wechtenbruch, Juliane
Suckfüll, Markus
Buske, Annegret
Bohring, Axel
Kubisch, Christian
Vogt, Stefanie
Strobl-Wildemann, Gertrud
Greally, Marie
Bartsch, Oliver
Steinberger, Daniela
author_facet Wildhardt, Gabriele
Zirn, Birgit
Graul-Neumann, Luitgard M
Wechtenbruch, Juliane
Suckfüll, Markus
Buske, Annegret
Bohring, Axel
Kubisch, Christian
Vogt, Stefanie
Strobl-Wildemann, Gertrud
Greally, Marie
Bartsch, Oliver
Steinberger, Daniela
author_sort Wildhardt, Gabriele
collection PubMed
description OBJECTIVES: Till date, mutations in the genes PAX3 and MITF have been described in Waardenburg syndrome (WS), which is clinically characterised by congenital hearing loss and pigmentation anomalies. Our study intended to determine the frequency of mutations and deletions in these genes, to assess the clinical phenotype in detail and to identify rational priorities for molecular genetic diagnostics procedures. DESIGN: Prospective analysis. PATIENTS: 19 Caucasian patients with typical features of WS underwent stepwise investigation of PAX3 and MITF. When point mutations and small insertions/deletions were excluded by direct sequencing, copy number analysis by multiplex ligation-dependent probe amplification was performed to detect larger deletions and duplications. Clinical data and photographs were collected to facilitate genotype–phenotype analyses. SETTING: All analyses were performed in a large German laboratory specialised in genetic diagnostics. RESULTS: 15 novel and 4 previously published heterozygous mutations in PAX3 and MITF were identified. Of these, six were large deletions or duplications that were only detectable by copy number analysis. All patients with PAX3 mutations had typical phenotype of WS with dystopia canthorum (WS1), whereas patients with MITF gene mutations presented without dystopia canthorum (WS2). In addition, one patient with bilateral hearing loss and blue eyes with iris stroma dysplasia had a de novo missense mutation (p.Arg217Ile) in MITF. MITF 3-bp deletions at amino acid position 217 have previously been described in patients with Tietz syndrome (TS), a clinical entity with hearing loss and generalised hypopigmentation. CONCLUSIONS: On the basis of these findings, we conclude that sequencing and copy number analysis of both PAX3 and MITF have to be recommended in the routine molecular diagnostic setting for patients, WS1 and WS2. Furthermore, our genotype–phenotype analyses indicate that WS2 and TS correspond to a clinical spectrum that is influenced by MITF mutation type and position.
format Online
Article
Text
id pubmed-3612789
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36127892013-07-08 Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics Wildhardt, Gabriele Zirn, Birgit Graul-Neumann, Luitgard M Wechtenbruch, Juliane Suckfüll, Markus Buske, Annegret Bohring, Axel Kubisch, Christian Vogt, Stefanie Strobl-Wildemann, Gertrud Greally, Marie Bartsch, Oliver Steinberger, Daniela BMJ Open Genetics and Genomics OBJECTIVES: Till date, mutations in the genes PAX3 and MITF have been described in Waardenburg syndrome (WS), which is clinically characterised by congenital hearing loss and pigmentation anomalies. Our study intended to determine the frequency of mutations and deletions in these genes, to assess the clinical phenotype in detail and to identify rational priorities for molecular genetic diagnostics procedures. DESIGN: Prospective analysis. PATIENTS: 19 Caucasian patients with typical features of WS underwent stepwise investigation of PAX3 and MITF. When point mutations and small insertions/deletions were excluded by direct sequencing, copy number analysis by multiplex ligation-dependent probe amplification was performed to detect larger deletions and duplications. Clinical data and photographs were collected to facilitate genotype–phenotype analyses. SETTING: All analyses were performed in a large German laboratory specialised in genetic diagnostics. RESULTS: 15 novel and 4 previously published heterozygous mutations in PAX3 and MITF were identified. Of these, six were large deletions or duplications that were only detectable by copy number analysis. All patients with PAX3 mutations had typical phenotype of WS with dystopia canthorum (WS1), whereas patients with MITF gene mutations presented without dystopia canthorum (WS2). In addition, one patient with bilateral hearing loss and blue eyes with iris stroma dysplasia had a de novo missense mutation (p.Arg217Ile) in MITF. MITF 3-bp deletions at amino acid position 217 have previously been described in patients with Tietz syndrome (TS), a clinical entity with hearing loss and generalised hypopigmentation. CONCLUSIONS: On the basis of these findings, we conclude that sequencing and copy number analysis of both PAX3 and MITF have to be recommended in the routine molecular diagnostic setting for patients, WS1 and WS2. Furthermore, our genotype–phenotype analyses indicate that WS2 and TS correspond to a clinical spectrum that is influenced by MITF mutation type and position. BMJ Publishing Group 2013-03-18 /pmc/articles/PMC3612789/ /pubmed/23512835 http://dx.doi.org/10.1136/bmjopen-2012-001917 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions this is an open-access article distributed under the terms of the creative commons attribution non-commercial license, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. see: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.
spellingShingle Genetics and Genomics
Wildhardt, Gabriele
Zirn, Birgit
Graul-Neumann, Luitgard M
Wechtenbruch, Juliane
Suckfüll, Markus
Buske, Annegret
Bohring, Axel
Kubisch, Christian
Vogt, Stefanie
Strobl-Wildemann, Gertrud
Greally, Marie
Bartsch, Oliver
Steinberger, Daniela
Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
title Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
title_full Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
title_fullStr Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
title_full_unstemmed Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
title_short Spectrum of novel mutations found in Waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
title_sort spectrum of novel mutations found in waardenburg syndrome types 1 and 2: implications for molecular genetic diagnostics
topic Genetics and Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612789/
https://www.ncbi.nlm.nih.gov/pubmed/23512835
http://dx.doi.org/10.1136/bmjopen-2012-001917
work_keys_str_mv AT wildhardtgabriele spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT zirnbirgit spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT graulneumannluitgardm spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT wechtenbruchjuliane spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT suckfullmarkus spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT buskeannegret spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT bohringaxel spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT kubischchristian spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT vogtstefanie spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT stroblwildemanngertrud spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT greallymarie spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT bartscholiver spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics
AT steinbergerdaniela spectrumofnovelmutationsfoundinwaardenburgsyndrometypes1and2implicationsformoleculargeneticdiagnostics